10
Sep
Ahead of oral argument in Louisiana v. U.S. Food and Drug Administration (FDA) on September 9, a wide range of experts — including the American College of Obstetricians and Gynecologists, American College of Emergency Physicians, the National Domestic Violence Hotline, the Disability Rights Education & Defense Fund, the NAACP Legal Defense & Educational Fund, pharmaceutical and biotech manufacturers, and former military officials — are urging the U.S. Court of Appeals for the Fifth Circuit to reject anti-abortion politicians’ effort to end telemedicine and mail and pharmacy access to mifepristone nationwide.Mifepristone is used in nearly two-thirds of U.S. abortions, with more than 1 in 4 patients
